Inovio Pharmaceuticals (NASDAQ:INO) Given New $15.00 Price Target at Oppenheimer

Inovio Pharmaceuticals (NASDAQ:INO) had its price objective lowered by Oppenheimer from $33.00 to $15.00 in a research report report published on Monday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock.

Separately, Royal Bank of Canada lowered their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $38.00.

Inovio Pharmaceuticals Trading Down 4.5 %

Shares of INO opened at $4.08 on Monday. The firm has a market capitalization of $105.79 million, a P/E ratio of -1.12 and a beta of 0.83. The stock’s fifty day simple moving average is $5.75 and its 200 day simple moving average is $8.14. Inovio Pharmaceuticals has a twelve month low of $4.07 and a twelve month high of $14.75.

Institutional Trading of Inovio Pharmaceuticals

Several large investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new position in Inovio Pharmaceuticals in the second quarter worth about $661,000. Signature Estate & Investment Advisors LLC bought a new stake in Inovio Pharmaceuticals during the second quarter worth approximately $88,000. Rhumbline Advisers raised its holdings in Inovio Pharmaceuticals by 5,943.0% during the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 37,857 shares in the last quarter. American Century Companies Inc. raised its holdings in Inovio Pharmaceuticals by 62.2% during the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 12,100 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in Inovio Pharmaceuticals in the second quarter worth approximately $184,000. 26.79% of the stock is currently owned by institutional investors and hedge funds.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.